Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Natera Inc

NTRA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Healthcare Facilities & Services ·

USA Large Cap Analyst: BUY

Last Close

$309.93

▼ -0.27%

Market Cap $44.67B · Vol 303.37K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$44.67B

Large Cap

Div Yield

N/A

EPS Growth

+0.36%

YoY

RSI (14)

72.04

Momentum

Beta

1.53

vs Market

52W High

$326.03

4.94% below

52W Low

$156.81

97.65% above

Volume

303.37K

Avg 344.95K

P/B

18.69

Price-to-book

ROE

-14.32%

Return on equity

Free Float

96.96%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Natera Inc (NTRA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NTRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.78%

+13.67%

+57.40%

+50.28%

YTD

+35.29%

+95.61%

+465.36%

+207.14%

Financials & Valuation

TTM · Annual

Total Revenue	$2.31B
Net Income	$-208,160,000.00
Revenue Growth (YoY)	+37.71%
Gross Margin	64.67%
Operating Margin	-13.27%
Net Profit Margin	-9.03%
ROE	-14.32%
ROA · ROIC	-13.21% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	13.58
P/B	18.69
P/FCF	411.51
EPS Growth	+0.36%
Outstanding Shares	144.14M

Technical Indicators

50-Day SMA	$262.30
200-Day SMA	$226.15
RSI (14)	72.04
Beta	1.53
52-Week High	$326.03
52-Week Low	$156.81

Volume Today	303.37K
Avg Daily Volume (30D)	344.95K
Relative Volume	0.88x
Volatility (10D)	97.22
Volatility (30D)	64.82
Free Float	96.96%

Analyst Consensus

BUY

Current Price $309.93

Mean Target $321.55

52W Low$156.81 52W High$326.03

Current

Target

$156.81 $326.03

Current Analyst target

+3.75% upside potential · 23 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0FSF8

ISINUS6323071042

CountryUnited States of America

Sub-IndustryMedical & Diagnostic Laboratories

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LH Labcorp Holdings Inc -1.38% RDNT RadNet Inc -1.24% LALPATHLAB.NS Dr. Lal PathLabs Ltd -2.65% WGS GeneDx Holdings Corp -1.35% 603882.SS Guangzhou Kingmed Diagnostics Group Co Ltd -1.57%

Company Profile

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.